Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Reducing the Risk of Late-Phase Failures

Posted on July 5th, 2016 by in Pharma R&D

Late-stage failures are common. The likelihood of a phase transition from Phase 2 to 3 is about 30%, and moving from Phase 3 to submission is only about 60% likely. The majority of late-stage failures are due to a lack of demonstrated efficacy (56%), followed by safety issues (28%)[1]. Continue reading “Reducing the Risk of Late-Phase Failures” »